Protas Company Profile

Background

Protas is a UK-based independent not-for-profit organization established in January 2022, dedicated to designing and delivering large-scale, global randomized clinical trials for treatments targeting common and life-threatening diseases. The organization aims to enhance patient care and public health outcomes by developing better treatments for conditions such as heart, lung, and respiratory diseases, arthritis, cancer, depression, and dementia.

Key Strategic Focus

Protas focuses on revolutionizing clinical trials by combining smart randomized trial design with effective technology and collaborative partnerships. The organization emphasizes:

Core Objectives: Reducing the complexity and cost of large-scale clinical trials to accelerate the development of treatments for prevalent diseases.

Areas of Specialization: Clinical trial design, management, and execution, particularly for common and life-threatening conditions.

Key Technologies Utilized: Protas has developed the Cantata platform, an innovative clinical trials management system built on Salesforce technology, which streamlines every aspect of clinical trial management within a single, secure system.

Primary Markets Targeted: Global healthcare systems, pharmaceutical companies, and research institutions involved in the development of treatments for widespread diseases.

Financials and Funding

In January 2022, Protas launched with French pharmaceutical company Sanofi as its first strategic partner. Sanofi committed up to £5 million (approximately $5.7 million) to support Protas's mission. As a not-for-profit organization, Protas's funding is primarily sourced from strategic partnerships and collaborations aimed at advancing clinical research.

Pipeline Development

Protas is actively engaged in the design and execution of large-scale clinical trials targeting common and life-threatening diseases. The organization has initiated trials focusing on conditions such as kidney disease, with the first trial using the Cantata platform commencing in September 2024. This trial is estimated to be the world's largest-ever pivotal phase 3 trial in kidney disease, affecting approximately 10% of the global population.

Technological Platform and Innovation

Protas has developed the Cantata platform, a unified clinical trials management system that integrates every stage of trial management into one secure system. Built on Salesforce technology, Cantata supports the entire process of running a clinical trial, from participant recruitment to data analysis. This platform significantly reduces the cost and complexity of large-scale trials, accelerating the development of treatments for common diseases.

Leadership Team

Protas is led by a team of experienced professionals committed to transforming clinical trials:

Prof Sir Martin Landray – Chief Executive Officer (CEO). A renowned figure in clinical research, Prof Landray has been instrumental in advancing large-scale clinical trials and is dedicated to improving global health through innovative research methodologies.

Kevin Hollingworth – Head of IT Development. Kevin leads the development of Protas's technological platforms, including the Cantata system, ensuring they meet the highest standards of efficiency and security.

Jennifer Dumbleton – Head of Trial Management and Product Owner. Jennifer oversees the design and execution of clinical trials, ensuring they align with Protas's mission to deliver high-quality, cost-effective research.

Competitor Profile

Market Insights and Dynamics

The clinical trials industry is experiencing a shift towards more efficient and cost-effective methodologies. Organizations like Protas are at the forefront of this transformation, aiming to reduce the complexity and expense associated with large-scale trials. The global burden of common diseases necessitates innovative approaches to accelerate the development of effective treatments.

Competitor Analysis

Protas operates in a competitive landscape that includes:

Verily – A subsidiary of Alphabet Inc., focusing on life sciences and healthcare research.

Groupe Multihealth – A clinical research organization specializing in the management of clinical trials.

CONVIDIA Clinical Research – A company offering clinical trial management services.

These competitors also aim to streamline clinical trial processes and improve the efficiency of medical research.

Strategic Collaborations and Partnerships

Protas's collaboration with Sanofi, which began in January 2022, has been pivotal in advancing its mission. Additionally, Protas partnered with Slalom, a global business and technology consulting company, to develop the Cantata platform. This partnership has been recognized with a Salesforce Partner Innovation Award in the "Healthcare & Life Sciences" category.

Operational Insights

Protas differentiates itself through its integrated approach to clinical trials, combining smart trial design with advanced technology and collaborative partnerships. The Cantata platform exemplifies this strategy, offering a unified system that enhances trial quality, improves user experience, and reduces costs. This operational model positions Protas as a leader in transforming clinical trials for better health outcomes.

Strategic Opportunities and Future Directions

Protas is poised to expand its impact by:

Scaling Up Operations: Increasing the number of large-scale trials conducted annually to address a broader range of common diseases.

Enhancing Technological Capabilities: Continuing to innovate and refine the Cantata platform to further streamline trial management processes.

Strengthening Partnerships: Building additional collaborations with pharmaceutical companies, research institutions, and healthcare providers to broaden the scope and reach of its clinical trials.